Q1 2024 Earnings Summary
Reported on Feb 18, 2025 (Before Market Open)
Pre-Earnings Price$234.33Last close (Apr 30, 2024)
Post-Earnings Price$243.00Open (May 1, 2024)
Price Change
$8.67(+3.70%)
- United Therapeutics is seeing significant growth in prescribing of Tyvaso for interstitial lung disease (ILD), with a 50% increase in breadth and a 30% increase in depth among ILD physicians over the last 15 months. The fully deployed expanded sales force is expected to further enhance this growth in the coming quarters.
- The company anticipates that the newly approved sotatercept will be used in combination with their existing prostacyclin therapies rather than replacing them. This could lead to patients staying on United Therapeutics' products longer, benefiting the company financially.
- United Therapeutics has a robust Xenotransplantation program with multiple products under development, including the Tianjin Xeno kidney and heart and the ThymoKidney. They have scientific rationale and preclinical evidence for both, and plan to conduct clinical studies for both products, potentially leading to multiple approvals and enhanced supply for patients.
- Competition in xenotransplantation could impact United Therapeutics as other companies are using different gene modification approaches, potentially more effective than UTHR's methods.
- The impending launch of sotatercept by Merck may introduce competition that could negatively affect sales of Tyvaso and other prostacyclin therapies, despite UTHR's belief that it will be complementary.
- Uncertainty about pricing pressures due to the Inflation Reduction Act in 2025, which the company did not fully address, could pose headwinds for UTHR's portfolio.
Research analysts covering UNITED THERAPEUTICS.